{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:33:43Z","timestamp":1763534023759,"version":"build-2065373602"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"am","delay-in-days":323,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002714","name":"Department of Nuclear Medicine, University Hospital Freiburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002714","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012353","name":"German Cancer Consortium","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008658","name":"German Cancer Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["PP00P2_163683"],"award-info":[{"award-number":["PP00P2_163683"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-StG-2015","676904"],"award-info":[{"award-number":["ERC-StG-2015","676904"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002714","name":"Research Commission of the University Freiburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002714","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fonds der chemischen Industrie"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.nucmedbio.2018.03.002","type":"journal-article","created":{"date-parts":[[2018,3,10]],"date-time":"2018-03-10T19:38:52Z","timestamp":1520710732000},"page":"45-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7746-1572","authenticated-orcid":false,"given":"Tilman","family":"L\u00e4ppchen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Kiefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason P.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Bartholom\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0005","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1021\/cr1000755","article-title":"Technetium and gallium derived radiopharmaceuticals: comparing and contrasting the chemistry of two important radiometals for the molecular imaging era","volume":"110","author":"Bartholoma","year":"2010","journal-title":"Chem Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.nucmedbio.2018.03.002_bb0010","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1007\/s00259-011-1988-5","article-title":"Feasibility and availability of (6)(8)Ga-labelled peptides","volume":"39","author":"Decristoforo","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/j.semnuclmed.2011.02.001","article-title":"(68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives","volume":"41","author":"Breeman","year":"2011","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cmmi.232","article-title":"68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals","volume":"3","author":"Fani","year":"2008","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0025","doi-asserted-by":"crossref","first-page":"12913","DOI":"10.3390\/molecules200712913","article-title":"68Ga-Based radiopharmaceuticals: production and application relationship","volume":"20","author":"Velikyan","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ica.2012.01.061","article-title":"Recent developments in the design of bifunctional chelators for metal-based radiopharmaceuticals used in positron emission tomography","volume":"389","author":"Bartholom\u00e4","year":"2012","journal-title":"Inorg Chim Acta"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/138161207779313768","article-title":"Copper chelation chemistry and its role in copper radiopharmaceuticals","volume":"13","author":"Wadas","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0040","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4155\/fmc.11.14","article-title":"The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86","volume":"3","author":"Ikotun","year":"2011","journal-title":"Future Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0045","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0969-8051(96)00130-8","article-title":"Copper radionuclides and radiopharmaceuticals in nuclear medicine","volume":"23","author":"Blower","year":"1996","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0050","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2967\/jnumed.112.112169","article-title":"Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin","volume":"54","author":"Dumont","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0055","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.2967\/jnumed.111.087700","article-title":"Novel Cu-64- and Ga-68-labeled RGD conjugates show improved pet imaging of alpha(v)beta(3) integrin expression and facile radiosynthesis","volume":"52","author":"Dumont","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0060","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1021\/jm401921j","article-title":"64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer","volume":"57","author":"Banerjee","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0065","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1021\/acs.bioconjchem.5b00049","article-title":"The ionic charge of copper-64 complexes conjugated to an engineered antibody affects biodistribution","volume":"26","author":"Dearling","year":"2015","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nucmedbio.2010.07.003","article-title":"Imaging cancer using PET\u2013the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody","volume":"38","author":"Dearling","year":"2011","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0075","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1021\/bc9000245","article-title":"18F, 64Cu, and 68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer","volume":"20","author":"Liu","year":"2009","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0080","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s00259-007-0692-y","article-title":"68Ga-labeled multimeric RGD peptides for microPET imaging of integrin \u03b1v\u03b23 expression","volume":"35","author":"Li","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0085","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1021\/bc700341x","article-title":"Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature","volume":"19","author":"Velikyan","year":"2008","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0090","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2967\/jnumed.107.047423","article-title":"Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)\u2013isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice","volume":"49","author":"Jeong","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0095","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1021\/bc2002665","article-title":"Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates","volume":"22","author":"Ait-Mohand","year":"2011","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0100","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.nucmedbio.2010.04.016","article-title":"Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model","volume":"37","author":"Lane","year":"2010","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0105","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7150\/thno.7324","article-title":"Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist\u2013from mice to men","volume":"4","author":"Wieser","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0110","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1002\/chem.200903281","article-title":"A triazacyclononane-based bifunctional phosphinate ligand for the preparation of multimeric 68Ga tracers for positron emission tomography","volume":"16","author":"Notni","year":"2010","journal-title":"Chem A Eur J"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0115","doi-asserted-by":"crossref","first-page":"14718","DOI":"10.1002\/chem.201103503","article-title":"TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals","volume":"17","author":"Notni","year":"2011","journal-title":"Chem A Eur J"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nucmedbio.2012.08.006","article-title":"Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of (6)(8)Ga-TRAP(RGD)(3)","volume":"40","author":"Notni","year":"2013","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0125","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1021\/bc900443a","article-title":"Evaluation of bifunctional chelates for the development of gallium-based radiopharmaceuticals","volume":"21","author":"Ferreira","year":"2010","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1021\/bc8004914","article-title":"(S)-5-(p-Nitrobenzyl)-PCTA, a promising bifunctional ligand with advantageous metal ion complexation kinetics","volume":"20","author":"Tircs\u00f3","year":"2009","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0135","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1021\/bc300348d","article-title":"68Ga Small peptide imaging: comparison of NOTA and PCTA","volume":"23","author":"Ferreira","year":"2012","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0140","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1021\/cr900104z","article-title":"Structural biology of copper trafficking","volume":"109","author":"Boal","year":"2009","journal-title":"Chem Rev"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0145","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1039\/b902210d","article-title":"Synthesis of a novel bifunctional chelator AmBaSar based on sarcophagine for peptide conjugation and (64)Cu radiolabelling","author":"Cai","year":"2009","journal-title":"Dalton Trans"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.nucmedbio.2009.09.001","article-title":"An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals","volume":"37","author":"Cai","year":"2010","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0155","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1039\/b605615f","article-title":"New 64Cu PET imaging agents for personalised medicine and drug development using the hexa-aza cage, SarAr","volume":"4","author":"Di Bartolo","year":"2006","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0160","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1039\/b103242a","article-title":"Synthesis of a new cage ligand, SarAr, and its complexation with selected transition metal ions for potential use in radioimaging","author":"Di Bartolo","year":"2001","journal-title":"J Chem Soc Dalton Trans"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0165","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1021\/jm030383m","article-title":"Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes","volume":"47","author":"Boswell","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0170","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2967\/jnumed.107.039487","article-title":"In vivo evaluation and small-animal PET\/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems","volume":"48","author":"Garrison","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0175","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2310\/7290.2009.00015","article-title":"Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide","volume":"8","author":"Hausner","year":"2009","journal-title":"Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0180","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1021\/jm070204r","article-title":"Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate imaging agents","volume":"50","author":"Sprague","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0185","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1021\/jm0103817","article-title":"Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands","volume":"45","author":"Sun","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0190","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1038\/nprot.2006.431","article-title":"Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64","volume":"1","author":"Wadas","year":"2006","journal-title":"Nat Protoc"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0195","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/bc800461e","article-title":"Hexadentate bispidine derivatives as versatile bifunctional chelate agents for copper(II) radioisotopes","volume":"20","author":"Juran","year":"2009","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0200","first-page":"17011","article-title":"Bispidines for dual imaging","volume":"20","author":"Stephan","year":"2014","journal-title":"Chemistry (Easton)"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0205","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.1021\/ic4008685","article-title":"Optimization of pentadentate bispidines as bifunctional chelators for 64Cu positron emission tomography (PET)","volume":"52","author":"Comba","year":"2013","journal-title":"Inorg Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0210","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/jlcr.3165","article-title":"Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals","volume":"57","author":"Cai","year":"2014","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0215","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.semnuclmed.2016.04.003","article-title":"Bifunctional gallium-68 chelators: past, present, and future","volume":"46","author":"Spang","year":"2016","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0220","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1021\/ic401607z","article-title":"Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals","volume":"53","author":"Zeglis","year":"2014","journal-title":"Inorg Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2310\/7290.2010.00008","article-title":"Unconventional nuclides for radiopharmaceuticals","volume":"9","author":"Holland","year":"2010","journal-title":"Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0230","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","article-title":"68Ga-Complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging","volume":"23","author":"Eder","year":"2012","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0235","first-page":"227","article-title":"Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen","volume":"53","author":"Israeli","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0240","first-page":"927","article-title":"Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients","volume":"7","author":"Horoszewicz","year":"1987","journal-title":"Anticancer Res"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0245","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1021\/jm010561g","article-title":"Molecular modeling of the interactions of glutamate carboxypeptidase II with its potent NAAG-based inhibitors","volume":"45","author":"Rong","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0250","doi-asserted-by":"crossref","first-page":"12711","DOI":"10.1021\/ja104591m","article-title":"A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules","volume":"132","author":"Zhang","year":"2010","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0255","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph7070779","article-title":"Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer","volume":"7","author":"Eder","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0260","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2967\/jnumed.115.158550","article-title":"68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies","volume":"56","author":"Weineisen","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0265","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2967\/jnumed.115.156133","article-title":"Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy","volume":"56","author":"Herrmann","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0270","doi-asserted-by":"crossref","first-page":"849","DOI":"10.7150\/thno.14744","article-title":"Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent","volume":"6","author":"Chatalic","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145755","article-title":"(R)-NODAGA-PSMA: a versatile precursor for radiometal labeling and nuclear imaging of PSMA-positive tumors","volume":"10","author":"Gourni","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0280","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","author":"Bene\u0161ov\u00e1","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0285","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1039\/C5RA21131J","article-title":"Synthesis, 64Cu-labeling and PET imaging of 1,4,7-triazacyclononane derived chelators with pendant azaheterocyclic arms","volume":"6","author":"Gotzmann","year":"2016","journal-title":"RSC Adv"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0290","doi-asserted-by":"crossref","DOI":"10.1021\/acs.inorgchem.7b01129","article-title":"Gallium complexation, stability, and bioconjugation of 1,4,7-triazacyclononane derived chelators with azaheterocyclic arms","author":"Schmidtke","year":"2017","journal-title":"Inorg Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0295","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.7150\/thno.18421","article-title":"Diagnostic accuracy of Ga-68-HBED-CC-PSMA-ligand-PET\/CT before salvage lymph node dissection for recurrent prostate cancer","volume":"7","author":"Jilg","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0300","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.2967\/jnumed.107.050203","article-title":"Routine quality controlof clinical nucliear medicine instrumentation: a brief review","volume":"49","author":"Zanzonico","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0305","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","article-title":"Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors","volume":"59","author":"Bene\u0161ov\u00e1","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0310","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2967\/jnumed.114.147181","article-title":"PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer","volume":"56","author":"Kratochwil","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0315","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1021\/jm800765e","article-title":"Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization","volume":"51","author":"Barinka","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0320","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.18632\/oncotarget.415","article-title":"A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA)","volume":"2","author":"Banerjee","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0325","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/sj.emboj.7600969","article-title":"Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer","volume":"25","author":"Mesters","year":"2006","journal-title":"EMBO J"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0330","first-page":"1366","article-title":"Establishment and characterization of monoclonal-antibodies against an octahedral gallium chelate suitable for immunoscintigraphy with pet","volume":"33","author":"Zoller","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0335","article-title":"New multidentate ligands.6. Chelating tendencies of N,N'-Di(2-hydroxybenzyl) ethylenediamine-N,N'-diacetic acid","volume":"89","author":"Leplatte","year":"1967","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0340","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1021\/acs.bioconjchem.5b00679","article-title":"Preclinical comparative study of Ga-68-labeled DOTA, NOTA, and HBED-CC chelated radiotracers for targeting PSMA","volume":"27","author":"Banerjee","year":"2016","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0345","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between inhibition constant (K1) and concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic-reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0350","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1021\/ic00202a019","article-title":"Crystallographic and thermodynamic study of metal-ion size selectivity in the ligand 1,4,7-triazacyclononane-N,N\u2032,N\u2033-triacetate","volume":"24","author":"Vandermerwe","year":"1985","journal-title":"Inorg Chem"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0355","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ica.2012.03.002","article-title":"Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: effects of chelate design on pharmacokinetics","volume":"389","author":"Maresca","year":"2012","journal-title":"Inorg Chim Acta"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0360","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2967\/jnumed.112.116624","article-title":"Tc-99m-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer","volume":"54","author":"Hillier","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0365","doi-asserted-by":"crossref","first-page":"10157","DOI":"10.1039\/c3ra47302c","article-title":"Establishment of two complementary in vitro assays for radiocopper complexes achieving reliable and comparable evaluation of in vivo stability","volume":"4","author":"Zarschler","year":"2014","journal-title":"RSC Adv"},{"key":"10.1016\/j.nucmedbio.2018.03.002_bb0370","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805117302676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805117302676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:28:23Z","timestamp":1760848103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805117302676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":74,"alternative-id":["S0969805117302676"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2018.03.002","relation":{},"ISSN":["0969-8051"],"issn-type":[{"type":"print","value":"0969-8051"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2018.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}